Baseline patient characteristics
| . | DMT (n = 72) . |
|---|---|
| Age, median (IQR), y | 67 (60-72) |
| Sex, n (%) | |
| Male | 44 (61) |
| Female | 28 (39) |
| Involved free light chain, n (%) | |
| λ | 54 (75) |
| κ | 18 (25) |
| Initial dFLC, median (IQR), mg/dL | 3.45 (1.8-10.7) |
| European 2015 addition to Mayo 2004 stage, n (%) | |
| Stage I | 10 (14) |
| Stage II | 37 (51) |
| Stage IIIA | 12 (17) |
| Stage IIIB | 5 (7) |
| Unable to calculate (missing data) | 8 (11) |
| Organ involvement, n (%) | |
| Heart | 57 (79) |
| Kidney | 47 (65) |
| Heart and kidney | 35 (49) |
| Liver | 5 (7) |
| Prior lines of therapy, median (IQR) | 2 (1-3) |
| Prior therapies/exposure, n (%) | |
| ASCT | 13 (18) |
| Upfront | 11 (15) |
| Salvage | 2 (3) |
| CyBorD | 50 (70) |
| Bortezomib | 69 (96) |
| Lenalidomide | 32 (44) |
| Carfilzomib | 14 (19) |
| Pomalidomide | 10 (14) |
| Ixazomib | 8 (11) |
| . | DMT (n = 72) . |
|---|---|
| Age, median (IQR), y | 67 (60-72) |
| Sex, n (%) | |
| Male | 44 (61) |
| Female | 28 (39) |
| Involved free light chain, n (%) | |
| λ | 54 (75) |
| κ | 18 (25) |
| Initial dFLC, median (IQR), mg/dL | 3.45 (1.8-10.7) |
| European 2015 addition to Mayo 2004 stage, n (%) | |
| Stage I | 10 (14) |
| Stage II | 37 (51) |
| Stage IIIA | 12 (17) |
| Stage IIIB | 5 (7) |
| Unable to calculate (missing data) | 8 (11) |
| Organ involvement, n (%) | |
| Heart | 57 (79) |
| Kidney | 47 (65) |
| Heart and kidney | 35 (49) |
| Liver | 5 (7) |
| Prior lines of therapy, median (IQR) | 2 (1-3) |
| Prior therapies/exposure, n (%) | |
| ASCT | 13 (18) |
| Upfront | 11 (15) |
| Salvage | 2 (3) |
| CyBorD | 50 (70) |
| Bortezomib | 69 (96) |
| Lenalidomide | 32 (44) |
| Carfilzomib | 14 (19) |
| Pomalidomide | 10 (14) |
| Ixazomib | 8 (11) |